Fibrinogen Concentrate in Obstetric Hemorrhage
DOI:
https://doi.org/10.25751/rspa.15976Keywords:
Blood Coagulation Disorders; Fibrinogen; Pregnancy Complications, Hematologic; Postpartum HemorrhageAbstract
Fibrinogen is a soluble plasmatic glycoprotein. Synthesized in hepatocytes and stored in platelets, it has a plasma concentration between 2-4,5 g/L, increasing in pregnancy, and a half-life of 4-7 days. It functions as an acute phase reactant and is determinant for an effective hemostasis. In hypofibrinogenemia, congenital or acquired, there are three possible approaches for the fill in of fibrinogen: fresh frozen plasma, cryoprecipitate and fibrinogen concentrate.
Fibrinogen concentrate has been used to control coagulopathy, contributing to lower the use of allogeneic blood products in major bleeding in various clinical settings. It is an important and effective hemostatic intervention, being considered a "potential universal hemostatic agent".
During pregnancy, marked changes in hemostasis are observed disposing to hypercoagulability, a physiological preparation for blood loss at birth. However these also facilitate thromboembolic events.
Obstetric hemorrhage is the leading cause of maternal morbidity and mortality, even in developed countries, and is the most preventable cause of mortality. Postpartum hemorrhage is the most common form. Massive hemorrhage in obstetrics is a critical event that requires an assertive interdisciplinary approach. The implementation of obstetric hemorrhage management protocols, with transfusion algorithms, has
led to reduction of morbidity, and should exist in all Obstetric Units. The various protocols differ in the hemostatic resuscitation strategy.
Decreased plasma fibrinogen levels appear to be a biomarker in predicting increased postpartum hemorrhage, so administration of fibrinogen concentrate is a key hemostatic intervention. There is still
no consensus regarding trigger and plasma targeting for fibrinogen replacement. The Portuguese Recommendations of the Portuguese Society of Anesthesiology of 2018 consider hypofibrinogenemia
in postpartum hemorrhage when: 1) fibrinogen ≤2.9 g/L; 2) FIBTEM maximum clot firmness ≤18 mm; 3) blood loss ≥1.5 L with continuous bleeding and laboratory results not yet available. They also recommend an initial dose of 25-50 mg/kg, with additional doses pending on clinical evolution and/or laboratory monitoring.
The increased use of fibrinogen concentrate, associated with pointof-care coagulation tests, significantly modified the therapeutic strategy in obstetric hemorrhage. Early and targeted correction of coagulopathy is associated with reduction of transfused blood components and related complications. Despite the unquestionable role of fibrinogen concentrate, some issues remain to be defined in order to provide a more precise treatment of obstetric hemorrhage
Downloads
References
2. Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg. 2012;114:261-74. doi: 10.1213/ANE.0b013e31822e1853.
3. Carvalhas J, Alves C, Tavares Ferreira C, Santos Silva I, Jorge Costa F, Palmira Almeida J, et al. Recomendações Portuguesas para a Abordagem Multidisciplinar da Hemorragia Obstétrica - Elaboradas por Grupo
Multidisciplinar de Consensos 2017. Rev Soc Port Anestesiol.2018;27:30-44.
4. de Lange NM, Lancé MD, de Groot R, Beckers EA, Henskens YM, Scheepers HC. Obstetric hemorrhage and coagulation: an update. Thromboelastography, thromboelastometry, and conventional coagulation tests in the diagnosis and prediction of postpartum hemorrhage. Obstet Gynecol Surv. 2012;67:426-35. doi: 10.1097/OGX.0b013e3182605861.
5. Ekelund K, Hanke G, Stensballe J, Wikkelsøe A, Albrechtsen CK, Afshari A. Hemostatic resuscitation in postpartum hemorrhage - a supplement to surgery. Acta Obstet Gynecol Scand. 2015;94:680-92. doi: 10.1111/aogs.12607.
6. Costa-Filho R, Hochleitner G, Wendt M, Teruya A, Spahn DR. Over 50 years of fibrinogen concentrate. Clin Appl Thromb Hemost. 2016;22:109-14. doi: 10.1177/1076029615601494.
7. Solomon C, Collis RE, Collins PW. Haemostatic monitoring during postpartum haemorrhage and implications for management. Br J Anaesth. 2012;109:851-63. doi: 10.1093/bja/aes361.
8. Kozek-Langenecker SA, Ahmed AB, Afshari A, Albaladejo P, Aldecoa C, Barauskas G, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. Eur J
Anaesthesiol. 2017;34:332-95. doi: 10.1097/EJA.0000000000000630.
9. Guasch E, Gilsanz F. Massive obstetric hemorrhage: Current approach to management. Med Intensiva. 2016;40:298-10. doi: 10.1016/j.medin.2016.02.010.
10. Ducloy-Bouthors AS, Susen S, Wong CA, Butwick A, Vallet B, Lockhart E. Medical advances in the treatment of postpartum hemorrhage. Anesth Analg. 2014;119:1140-7. doi: 10.1213/ANE.0000000000000450.
11. Lockhart E. Postpartum hemorrhage: a continuing challenge. Hematology Am Soc Hematol Educ Program. 2015;2015:132-7. doi: 10.1182/ asheducation-2015.1.132.
12. Carvalho M, Rodrigues A, Gomes M, Carrilho A, Nunes AR, Orfão R, et al. Interventional algorithms for the control of coagulopathic bleeding in surgical, trauma, and postpartum settings: recommendations from
the share network group. Clin Appl Thromb Hemost. 2016;22:121-37. doi: 10.1177/1076029614559773.
13. Butwick AJ, Goodnough LT. Transfusion and coagulation management in major obstetric hemorrhage. Curr Opin Anaesthesiol. 2015;28:275-84. doi: 10.1097/ACO.0000000000000180.
14. Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost. 2007;5:266-73.
15. Collins PW, Lilley G, Bruynseels D, Laurent DB, Cannings-John R, Precious E, et al. Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. Blood. 2014;124:1727-36. doi: 10.1182/blood-2014-04-567891
16. Matsunaga S, Takai Y, Nakamura E, Era S, Ono Y, Yamamoto K, et al. The clinical efficacy of fibrinogen concentrate in massive obstetric haemorrhage with hypofibrinogenaemia. Sci Rep. 2017;7:46749. doi: 10.1038/srep46749.
17. Cortet M, Deneux-Tharaux C, Dupont C, Colin C, Rudigoz RC, Bouvier-Colle MH, et al. Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. Br J Anaesth.
2012;108:984-9. doi: 10.1093/bja/aes096.
18. Collins P, Cannings-John R, Bruynseels D, Mallaiah S, Dick J, Elton C, et al. Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial. Br J of Anaesth. 2017;119:411–21. doi: 10.1093/bja/aex181.
19. Ickx B, Samama CM. Fibrinogen concentrates for post-partum haemorrhage? Do not miss the most relevant population! Br J Anaesth. 2015;114:548-50. doi: 10.1093/bja/aev033.
20. Marques S, Cabral R, Fonseca J, Pereira M, Alves C, Carvalhas J. Hemorragia massiva em obstetrícia: Princípios chave. Rev Soc Port Anestesiol. 2015;24:12-9.
21. McDonnell NJ, Browning R. How to replace fibrinogen in postpartum haemorrhage situations? (Hint: Don't use FFP!). Int J Obstet Anesth. 2018;33:4-7. doi: 10.1016/j.ijoa.2017.08.008.
Downloads
Published
How to Cite
Issue
Section
License
Articles are freely available to be read, downloaded and shared from the time of publication.
The RSPA reserves the right to commercialize the article as an integral part of the journal (in the preparation of reprints, for example). The author should accompany the submission letter with a declaration of copyright transfer for commercial purposes.
Articles are published under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC).
After publication in RSPA, authors are allowed to make their articles available in repositories of their home institutions, as long as they always mention where they were published.
